Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polypeptide N-acetylgalactosaminyltransferase 10 (GALNT10) is an enzyme that catalyzes the first step in the synthesis of mucin-type O-linked oligosaccharides by transferring N-acetyl-D-galactosamine from UDP-GalNAc to serine or threonine residues on polypeptide substrates[1][3][7]. This enzymatic activity is essential for the O-glycosylation of proteins, a critical post-translational modification that regulates protein stability, localization, and function[6][7]. GALNT10 has higher catalytic activity for certain glycosylated peptide substrates and is involved in various physiological processes, with disease associations that include cancer (such as roles in proliferation, metastasis, and chemoresistance in gastric cancer) and rare genetic disorders like isolated ectopia lentis[1][5][7]. GALNT10 belongs to the glycosyltransferase family and its dysfunction may contribute to disease pathogenesis through aberrant glycosylation[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polypeptide N-acetylgalactosaminyltransferase 10 (GALNT10).